| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 36784 | Trends in Biotechnology | 2015 | 4 Pages |
Abstract
The Spanish Agency of Medicines and Medical Devices (AEMPS) has drawn up a comprehensive report and resolution that regulates for the first time the use of platelet-rich plasma (PRP) as a human-use medicinal product. This regulatory framework offers emerging challenges to adapt the use of PRP to the new requirements of safety and efficacy. The heterogeneity of the different products can hinder their regulation, which today differs substantially in the different worldwide regulatory frameworks.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Eduardo Anitua, Roberto Prado, Gorka Orive,